Management holds CFT7455 Phase 1 update investor conference call on December 12 at 4:30 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CCCC:
- C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
- C4 Therapeutics appoints Hughes to board of directors
- C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
- C4 Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
- C4 Therapeutics price target lowered to $7 from $17 at H.C. Wainwright